

# Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause

NCT07118891

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	AbCellera Biologics Inc.
Enrollment	136 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Good general health as determined through a review of their medical history and after conducting a general physical examination
- Body weight e 45 to d 120 kg
- Body mass index (BMI) between 18.5 kg/m<sup>2</sup> and 35.0 kg/m<sup>2</sup>
- Non- or ex-smoker (an ex-smoker is defined as someone who completely stopped using nicotine products for at least 90 days prior to the first study drug administration)
- Healthy man or a postmenopausal woman who is e 40 and d 75 years of age OR a postmenopausal woman with or without VMS and who is e 40 and d 75 years of age OR a postmenopausal woman who is e 40 and d 75 years of age seeking treatment for relief for VMS

... and 6 more (see full listing online)

### Exclusion (11)

- Pregnancy and/or lactation.
- Has endometrial hyperplasia or history of abnormal uterine bleeding without an identified cause in the past 6 months
- Previous or current history of a malignant tumor, except for non-melanoma skin cancer.
- Seated pulse rate less than 50 beats per minute (bpm) or more than 100 bpm or a seated blood pressure < 90/50 mmHg or > 140/90 mmHg
- eGFR < 60 mL/min/1.73 m<sup>2</sup>

... and 6 more (see full listing online)

## Locations (10 total)

---

CaRe Clinics, Red Deer, Alberta, Canada

Mount Saint Joseph Hospital Clinical Trials Phase 1 Unit, Vancouver, British Columbia, Canada

Centricity Research, Toronto, Ontario, Canada

... and 7 more locations